Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMemory changes are not listed among Wegovy's known or common side effects under its UK licence, and current clinical evidence does not identify semaglutide as a cause of memory loss or cognitive decline. That said, some people starting treatment do notice short-lived difficulties with focus — usually tied to the adjustment phase rather than the medicine itself. Wegovy is a prescription-only medicine; a GPhC-registered prescriber reviews your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting point is the official record. Wegovy's licensed side-effect profile, set out in its Summary of Product Characteristics and reflected on the NHS semaglutide medicines page, lists nausea, vomiting, diarrhoea, constipation, headache, dizziness, and fatigue among the common effects. Memory impairment, brain fog, and cognitive changes are not among them. That absence matters: regulators require manufacturers to report adverse effects seen in trials, and the STEP trial programme (which underpins Wegovy's UK licence) did not identify memory or concentration problems as a pattern to report.
There is a separate, broader question about GLP-1 medicines and brain health that researchers are actively investigating, and our dedicated page on semaglutide and memory loss covers what the current evidence does and does not show. Early observational data have pointed toward possible neuroprotective signals in some groups, particularly people with type 2 diabetes, but this remains preliminary science. It does not change what is currently licensed or what Wegovy is prescribed for.
So the direct answer to this keyword is: no, Wegovy is not known to affect memory. That distinction matters when you are deciding how to interpret what you feel during the first weeks of treatment.
People do sometimes describe a foggy or slow feeling in the early weeks of Wegovy, even if the medicine is not the direct cause. The more common explanations are worth working through in order.
Calorie restriction is usually first. Semaglutide suppresses appetite significantly, and some people eat far less than they realise, particularly in the first few weeks. The brain runs on glucose, and a sudden, sharp reduction in food intake can produce fatigue, difficulty concentrating, and a feeling of mental sluggishness that is easy to attribute to the injection rather than to what you ate that day. Staying adequately nourished, even when appetite is low, tends to resolve it quickly.
Nausea is another contributor. When you feel persistently sick, concentration suffers. Poor sleep, which GI discomfort can cause, compounds this. These are well-recognised effects of the adjustment period across semaglutide treatment more broadly, and they typically ease as the body settles.
Dehydration is underestimated. If nausea or vomiting leads to reduced fluid intake, cognitive sharpness can drop noticeably. Keeping fluid intake steady matters more during the early titration phase than most people expect.
Most transient brain-fog resolves within two to four weeks as the body adjusts and eating patterns stabilise. But some symptoms deserve a more direct response. Sudden, severe confusion or an abrupt change in mental clarity is not typical of Wegovy's adjustment profile and warrants same-day medical advice. Likewise, persistent low mood or thoughts of self-harm should be discussed with a clinician promptly, the MHRA's Yellow Card scheme allows patients to report suspected side effects, and doing so helps build the evidence base for everyone on these medicines.
If you are prescribed Wegovy alongside HRT, it is worth knowing that GLP-1 medicines can affect the absorption of oral medications. Our page on Wegovy and HRT covers this in more detail, including the NHS guidance on switching to transdermal formulations where appropriate.
Changes in taste perception are another thing people notice early on, not a memory effect but sometimes described that way. That topic has its own dedicated page on how Wegovy affects taste if it is relevant to you.
If you are mid-treatment and genuinely uncertain whether a symptom is coming from Wegovy, from what you are eating, or from something unrelated, the right move is a conversation with a clinician who knows your full history. That is not a reason to stop treatment without advice, stopping abruptly and restarting later disrupts progress and carries its own risks.
At nume, aftercare is available seven days a week so that questions like this one get a real answer from a prescriber, not an automated message. A question our prescribers hear regularly is whether brain fog means treatment should stop. Usually, it doesn't. The context matters (what you've been eating, how sleep has been, whether nausea has been severe) and a short conversation usually resolves it.
If you are exploring whether Wegovy could be right for you, our Wegovy pricing page sets out what is included in a private prescription through a GPhC-registered pharmacy. And if you want to understand the broader picture of weight-loss treatment options in the UK, that is a useful starting point before committing to anything. When you are ready, checking eligibility takes a few minutes and costs nothing.
Check your eligibility with a free consultation through our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.